Brittany C. Waschke
Rachel A Woolaver
Samantha M. Y. Chen
Zhangguo Chen
Jing H. Wang
Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, School of Medicine, 12800 E. 19 th Ave, Mail Stop 8333, Aurora, CO 80045, USA
Funds: This work was supported by University of Colorado School of Medicine and Cancer Center startup funds to J.H.W., Cancer League of Colorado, R21-CA184707, R21-AI110777, R01-CA166325, R21-AI133110 and R01-CA229174 to J.H.W., and a fund from American Cancer Society (ACS IRG #16-184-56) to Z.C. X.G.W. was supported by an AAI Careers in Immunology Fellowship. R.A.W. is supported by a NIH F31 fellowship (F31DE027854). S.M.Y.C. is supported by a NIH T32 fellowship (T32 AI007405).
Received Date: 2019-12-03
Abstract
Abstract
Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment. To overcome this issue, combinatorial therapeutic strategies have been pursued to achieve a better efficacy for treating B-cell lymphomas. One of such strategies is to combine immunotherapy with histone deacetylase (HDAC) inhibitors. HDAC inhibitors can potentially increase tumor immunogenicity, promote anti-tumor immune responses, or reverse immunosuppressive tumor environments. Thus, the combination of HDAC inhibitors and immunotherapy has drawn much attention in current cancer treatment. However, not all HDAC inhibitors are created equal and their net effects are highly dependent on the specific inhibitors used and the HDACs they target. Hence, we suggest that optimal treatment efficacy requires personalized design and rational combination based on prognostic biomarkers and unique profiles of HDAC inhibitors. Here, we discuss the possible mechanisms by which B-cell lymphomas acquire immunotherapy resistance and the effects of HDAC inhibitors on tumor cells and immune cells that could help overcome immunotherapy resistance.Keywords: cancer immunotherapy,
HDAC inhibitor,
Bcell lymphomas,
anti-PD1 resistance,
tumor immunogenicity
PDF全文下载地址:
http://www.protein-cell.org/article/exportPdf?id=07b174de-f46d-48ea-86fb-ab76211897e0&language=en
